52 Week Trial of Liraglutide in Type 1 Diabetes

NCT01787916 on ClinicalTrials.gov · last registry update 2018-01-05

A small phase 4 — 15 participants, against a typical 75. The sponsor logged completion for April 2015. Primary outcome, as filed: Assessment of Changes in Glycemic Control by HbA1c. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: CHU de Quebec-Universite Laval
Sponsor type: Other
Enrollment: 15
Started: 2013-04
Primary completion: 2015-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Assessment of Changes in Glycemic Control by HbA1c.

Conditions studied

Type 1 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.